Table 3.
Variable | IIFE | EF | QS-M | |||
R | p | R | p | R | p | |
Age (y) | –0.120 | >0.05 | –0.202 | >0.05 | –0.117 | >0.05 |
SEC | 0.215 | >0.05 | 0.143 | >0.05 | 0.198 | >0.05 |
Disease duration (y) | –0.326 | 0.003 | –0.262 | 0.018 | –0.154 | >0.05 |
H&Y | –0.432 | 0.001 | –0.340 | 0.001 | –0.295 | 0.007 |
DDL (mg/day) | –0.221 | >0.05 | –0.118 | >0.05 | –0.097 | >0.05 |
DDAL (mg/day) | –0.157 | >0.05 | –0.206 | >0.05 | –0.062 | >0.05 |
DDS | 0.081 | >0.05 | 0.068 | >0.05 | 0.021 | >0.05 |
TMOCA | 0.413 | 0.001 | 0.359 | 0.001 | 0.252 | 0.024 |
MDS-UPDRS I | –0.413 | 0.001 | –0.372 | 0.000 | –0.328 | 0.002 |
MDS-UPDRS II | –0.055 | 0.001 | –0.478 | 0.000 | –0.411 | 0.000 |
FSS | –0.438 | 0.001 | –0.320 | 0.003 | –0.343 | 0.001 |
PDSS | 0.444 | 0.001 | 0.379 | 0.001 | 0.333 | 0.002 |
DAS | 0.101 | >0.05 | 0.115 | >0.05 | 0.283 | 0.023 |
BDI | –0.385 | 0.001 | –0.233 | 0.037 | –0.290 | 0.008 |
RSES | –0.38 | 0.001 | –0.268 | 0.016 | –0.297 | 0.007 |
IIEF, International Index of Erectile Function; EF, erectile function; QS-M, Sexual Quotient-Male; SEC, socio-economic condition; H&Y, Hoehn and Yahr Stage; DDL, daily dosage levodopa; DDAL, daily dosage agonist levodopa; DDS, Dopaminergic Dysregulation Syndrome; T-MoCA, Telephone-Montreal Cognitive Assessment; MDS-UPDRS, Movement Disorder Society–Unified Parkinson’s Disease Rating Scale; FSS, Fatigue Severity Scale; PDSS, Parkinson’s Disease Sleep Scale; DAS, Dyadic Adjustment Scale; BDI, Beck Depression Inventory; RSES, Rosemberg’s Self-esteem Scale.